Stifel Nicolaus Boosts Insulet (NASDAQ:PODD) Price Target to $293.00

Insulet (NASDAQ:PODD) had its target price lifted by equities researchers at Stifel Nicolaus from $245.00 to $293.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has a “hold” rating on the medical instruments supplier’s stock. Stifel Nicolaus’ target price points to a potential upside of 3.61% from the stock’s current price.

Other equities analysts also recently issued reports about the stock. JPMorgan Chase & Co. lifted their price target on shares of Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a report on Thursday, December 12th. Piper Sandler boosted their target price on shares of Insulet from $285.00 to $310.00 and gave the stock an “overweight” rating in a research note on Friday. Canaccord Genuity Group boosted their target price on shares of Insulet from $304.00 to $324.00 and gave the stock a “buy” rating in a research note on Friday. Morgan Stanley boosted their target price on shares of Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a research note on Monday, November 11th. Finally, TD Cowen boosted their target price on shares of Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a research note on Friday, January 3rd. Three research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $289.06.

Insulet Trading Down 1.9 %

Shares of PODD stock opened at $282.80 on Friday. Insulet has a 12-month low of $160.19 and a 12-month high of $289.46. The company has a market capitalization of $19.84 billion, a P/E ratio of 48.84, a P/E/G ratio of 3.62 and a beta of 1.23. The firm has a 50-day moving average price of $272.98 and a 200 day moving average price of $247.46. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.15. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The firm had revenue of $597.50 million during the quarter, compared to the consensus estimate of $582.02 million. Research analysts forecast that Insulet will post 3.92 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CAO Lauren Budden sold 915 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the transaction, the chief accounting officer now owns 5,733 shares in the company, valued at approximately $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Eric Benjamin sold 12,394 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the transaction, the executive vice president now owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. This represents a 52.13 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. American Trust acquired a new position in Insulet during the fourth quarter valued at approximately $210,000. Mackenzie Financial Corp boosted its holdings in shares of Insulet by 7.0% in the fourth quarter. Mackenzie Financial Corp now owns 7,561 shares of the medical instruments supplier’s stock valued at $1,974,000 after buying an additional 493 shares during the period. Peak Retirement Planning Inc. acquired a new position in shares of Insulet in the fourth quarter valued at approximately $1,063,000. Toronto Dominion Bank boosted its holdings in shares of Insulet by 55.2% in the fourth quarter. Toronto Dominion Bank now owns 36,486 shares of the medical instruments supplier’s stock valued at $9,526,000 after buying an additional 12,984 shares during the period. Finally, GF Fund Management CO. LTD. acquired a new position in shares of Insulet in the fourth quarter valued at approximately $439,000.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.